Ernexa Therapeutics (ERNAW) Net Income towards Common Stockholders (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Net Income towards Common Stockholders of -$5.5 million for Q1 2026, up 32.87% on a YoY basis from -$4.1 million in Q1 2025, and down 264.64% quarter-over-quarter from -$1.5 million in Q4 2025.
Ernexa Therapeutics (ERNAW) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$5.5 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 32.87% year-over-year to -$5.5 million; the trailing twelve-month figure through Mar 2026 stood at -$11.4 million (up 75.27% YoY), and the FY2025 full-year result was -$14.1 million, up 68.35% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$5.5 million, down from -$1.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was -$1.2 million in Q3 2025, with the low at -$26.6 million in Q3 2024.
- Historically, Net Income towards Common Stockholders has averaged -$6.5 million across 5 years, with a median of -$5.5 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders plunged 375.84% — and 2025, when it soared 95.34%.
- Ernexa Therapeutics' Net Income towards Common Stockholders stood at -$4.5 million in 2022, then tumbled by 37.0% to -$6.2 million in 2023, then advanced by 6.4% to -$5.8 million in 2024, then jumped by 73.82% to -$1.5 million in 2025, then slumped by 264.64% to -$5.5 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$5.5 million (Q1 2026), -$1.5 million (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Ernexa Therapeutics | - | - | - | -5.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.51 Mn |
| Dec 31, 2025 | -1.51 Mn |
| Sep 30, 2025 | -1.24 Mn |
| Jun 30, 2025 | -3.15 Mn |
| Mar 31, 2025 | -8.20 Mn |
| Dec 31, 2024 | -5.77 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -5.54 Mn |
| Mar 31, 2024 | -6.65 Mn |
| Dec 31, 2023 | -6.16 Mn |
| Sep 30, 2023 | -5.59 Mn |
| Jun 30, 2023 | -4.52 Mn |
| Mar 31, 2023 | -5.42 Mn |
| Dec 31, 2022 | -4.50 Mn |
| Sep 30, 2022 | -7.32 Mn |
| Jun 30, 2022 | -3.41 Mn |
| Mar 31, 2022 | -9.38 Mn |
| Dec 31, 2021 | -7.96 Mn |
| Sep 30, 2021 | -85.99 Mn |
| Jun 30, 2021 | -10.09 Mn |